Investigational drug · Phase 2
HMPL-689
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed/Refractory Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "HMPL-689"
First trial start
2023
Feb 13, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMPL-689", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed/Refractory Lymphoma
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "HMPL-689" as an intervention, largest first.
Hutchison Medipharma LimitedIndustry
NCT03128164 · 200 participants · Start Aug 8, 2017 · Primary completion Aug 2, 2023
Drug: HMPL-689 · For: Lymphomas
Sites: Wuhan, China; Guangzhou, China; Shanghai, China
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompleted
Hutchison Medipharma LimitedIndustry
NCT04849351 · 178 participants · Start Apr 15, 2021 · Primary completion Feb 29, 2024
Drug: HMPL-689 · For: Marginal Zone Lymphoma; Follicular Lymphoma
Sites: Hefei, China; Beijing, China; Chongqing, China · 58 sites in all
- A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaCompleted
HutchmedIndustry
NCT05713110 · 61 participants · Start Feb 13, 2023 · Primary completion Dec 31, 2024
Drug: tazemetostat; HMPL-689 · For: Relapsed/Refractory Lymphoma
Sites: Shanghai, China
HutchmedIndustry
NCT05602597 · 59 participants · Start Jun 1, 2022 · Primary completion Aug 6, 2022
Drug: Itraconazole 200 mg; Fluconazole 400 mg and 2 more · For: Relapsed or Refractory Lymphoma
Sites: Miami, Florida
HutchmedIndustry
NCT03786926 · 53 participants · Start Aug 26, 2019 · Primary completion Jun 26, 2024
Drug: HMPL-689 · For: Lymphoma
Sites: Anaheim, California; Oxnard, California; Atlanta, Georgia · 27 sites in all
Hutchison Medipharma LimitedIndustry
NCT02631642 · 48 participants · Start Mar 23, 2016 · Primary completion Oct 26, 2016
Drug: HMPL-689; HMPL-689 placebo · For: Healthy Volunteers
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin's lymphoma, in healthy Chinese volunteers.
Zhao CY, Zhang LJ, Sun C, et al. · Front Pharmacol 2024
- Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies.
Jiang S, Li X, Xue W, et al. · Front Pharmacol 2024
- Effect of a high-fat meal on the relative bioavailability of HMPL-689 in Chinese healthy volunteers.
Cao W, Ding Q, Wang Y, et al. · Fundam Clin Pharmacol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.